Green Valley Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Green Valley Pharma - overview
Established
2018
Location
Shanghai, -, China
Primary Industry
Healthcare Specialists
About
Green Valley Pharma, based in Shanghai, China, is dedicated to delivering innovative cognitive health solutions aimed at treating cognitive disorders, enhancing the quality of life for affected individuals. Founded in 2018 in Shanghai, China, Green Valley Pharma specializes in cognitive health solutions. The company has engaged in one notable deal, with Shanghai Fosun Pharmaceutical (Group) agreeing to acquire a majority 51% stake for CNY 1. 41 billion on December 15, 2025.
The company has not undergone any notable pivots or changes in its operational strategy since its inception. GreenValley Pharmaceuticals Co. , Ltd. specializes in innovative cognitive health solutions, focusing on the treatment of cognitive disorders such as Alzheimer's disease, vascular dementia, Parkinson's disease, and autism spectrum disorders.
The company leverages research in the gut-brain axis and artificial intelligence to develop therapeutic products aimed at enhancing cognitive function. Green Valley's offerings target healthcare providers like hospitals and specialist clinics, with a significant presence in the Chinese healthcare market, particularly within the Shanghai Free Trade Zone. GreenValley operates through a structured transactional framework involving partnerships with healthcare institutions and direct sales to medical facilities. This B2B revenue model primarily includes contracts with hospitals and clinics for its therapeutic solutions.
Pricing agreements are negotiated to meet the needs of healthcare providers procuring these products for their patients. Additionally, GreenValley may collaborate with research institutions to validate its product efficacy, supporting sustainable revenue growth. Green Valley Pharma plans to leverage its recent acquisition by Shanghai Fosun Pharmaceutical (Group) to focus on unmet clinical needs and enhance its innovative product pipeline in central nervous system treatments. The CNY 1.
41 billion funding will be utilized to create integrated diagnostic and treatment solutions. Furthermore, the company is poised to expand its market presence within China and potentially into new regions, aligning its product development efforts to meet evolving healthcare demands. The strategic goals set for 2025 include the launch of new products aimed at addressing various cognitive disorders.
Primary Industry
Healthcare Specialists
Sub Industries
Healthcare, Oncology/Cancer Treatment, Healthcare Specialists, Pharmaceuticals
Website
www.greenvalleypharma.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Green Valley Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Announced | Green Valley Pharma | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.